Arsanis Announces Pricing of Initial Public Offering
16 November 2017 - 5:20AM
Arsanis, Inc., a clinical-stage biopharmaceutical company focused
on applying monoclonal antibody immunotherapies to address serious
infectious diseases, today announced the pricing of its initial
public offering of 4,000,000 shares of its common stock at a public
offering price of $10.00 per share. The gross proceeds to Arsanis
from the offering are expected to be $40.0 million, before
deducting underwriting discounts and commissions and other offering
expenses. In addition, Arsanis has granted the underwriters a
30-day option to purchase up to 600,000 additional shares of common
stock from Arsanis at the public offering price, less underwriting
discounts and commissions, to cover over-allotments, if any. All of
the shares are being offered by Arsanis. Arsanis’ shares are
scheduled to begin trading on The NASDAQ Global Market on November
16, 2017 under the ticker symbol “ASNS.”
The offering is expected to close on November 20, 2017, subject
to customary closing conditions.
In addition, a fund affiliated with New Enterprise Associates
has agreed to purchase $20.0 million of Arsanis' common stock in a
separate private placement concurrent with the completion of
Arsanis' initial public offering at a price per share equal to the
initial public offering price. The closing of the initial public
offering is not conditioned upon the closing of the concurrent
private placement.
Citigroup, Cowen and Company and Piper Jaffray & Co. are
acting as joint book-running managers for the public offering and
as placement agents for the concurrent private placement.
A registration statement relating to the securities to
be offered and sold in the initial public offering has been filed
with, and was declared effective by, the Securities and Exchange
Commission on November 15, 2017. Copies of the registration
statement can be accessed by visiting the Securities and Exchange
Commission website at www.sec.gov.
This offering is being made only by means of a prospectus.
A preliminary prospectus describing the terms of the offering has
been filed with the Securities and Exchange Commission and forms a
part of the effective registration statement. A copy of the
final prospectus relating to the offering will be filed with the
Securities and Exchange Commission, and may be obtained, when
available, from Citigroup, c/o Broadridge Financial Solutions, 1155
Long Island Avenue, Edgewood, NY 11717, or by telephone at (800)
831-9146; Cowen and Company, LLC, c/o Broadridge Financial
Solutions, Attention: Prospectus Department, 1155 Long Island
Avenue, Edgewood, NY 11717, or by telephone at (631) 274-2806; or
Piper Jaffray & Co., Attention: Prospectus Department, 800
Nicollet Mall, J12S03, Minneapolis, MN 55402, by telephone at (800)
747-3924, or by email at prospectus@pjc.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of,
these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to the registration or
qualification under the securities laws of such state or
jurisdiction.
About Arsanis
Arsanis, Inc. is a clinical-stage biopharmaceutical company
focused on applying monoclonal antibody (mAb) immunotherapies to
address serious infectious diseases. A deep understanding of the
pathogenesis of infection, paired with access to some of the most
advanced mAb discovery techniques and platforms available today,
has positioned Arsanis to build and advance a pipeline of novel
mAbs with multiple mechanisms of action and high potency against
their intended targets. The company’s lead clinical program,
ASN100, is aimed at serious Staphylococcus aureus infections and is
being evaluated in a Phase 2 clinical trial for the prevention of
S. aureus pneumonia in high-risk, mechanically ventilated patients.
In addition to ASN100, its preclinical pipeline is comprised of
mAbs targeting multiple serious bacterial and viral pathogens,
including respiratory syncytial virus.
Arsanis is a U.S. company headquartered in Waltham,
Massachusetts, with European research and preclinical development
operations headquartered in Vienna, Austria (Arsanis Biosciences
GmbH).
Forward-Looking StatementsThis press release
includes certain disclosures which contain “forward-looking
statements,” including, without limitation, statements regarding
the anticipated timing of completion of the offerings of Arsanis’
common stock. You can identify forward-looking statements because
they contain words such as “believes” and “expects.”
Forward-looking statements are based on Arsanis’ current
expectations and assumptions. Because forward-looking statements
relate to the future, they are subject to inherent uncertainties,
risks and changes in circumstances that may differ materially from
those contemplated by the forward-looking statements, which are
neither statements of historical fact nor guarantees or assurances
of future performance. Important factors that could cause actual
results to differ materially from those in the forward-looking
statements are set forth in Arsanis’ filings with the SEC,
including its registration statement on Form S-1, as amended from
time to time, under the caption “Risk Factors.”
Media Contact:Ten Bridge CommunicationsKrystle
Gibbskrystle@tenbridgecommunications.com, 508-479-6358
Investor Contact:Michael GrayChief Operating
and Chief Financial Officermike.gray@arsanis.com, 781-819-5201
Actelis Networks (NASDAQ:ASNS)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Actelis Networks (NASDAQ:ASNS)
Historical Stock Chart
Von Jul 2023 bis Jul 2024